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1  | INTRODUC TION
Patients with refractory epilepsy comprise approximately 30% of all 
patients with epilepsy (Kwan & Brodie, 2000). Resective surgery is 
the treatment of choice for this patient group with focal epilepsy, 
but only 10- 30% of patients are eventually amenable for surgery. 
Optimizing the pharmacological treatment can make some of these 
patients seizure free (Liimatainen, Raitanen, Ylinen, Peltola, & 
Peltola, 2008), but possibilities for major improvement with antiepi-
leptic drug (AED) therapy are limited. Neurostimulation has offered 
new treatment options in refractory epilepsy, first with vagus nerve 
stimulation (VNS) and later with deep brain stimulation (DBS) of the 
anterior nucleus of the thalamus (ANT).
VNS delivers an electrical current to the 10th cranial nerve via 
electrode, wrapped around surgically the exposed vagal nerve. 
Currently, VNS devices are being implanted in patients with refrac-
tory seizures who cannot have resective surgery or who have had 
surgery with poor results. Moreover, many of these patients have 
been treated with several antiepileptic drugs before receiving VNS 
implants (Ben- Menachem, 2002). The biological mechanisms causing 
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Abstract
Objectives: Neurostimulation has offered new treatment options in refractory epi-
lepsy, first with vagus nerve stimulation (VNS) and more recently with deep brain 
stimulation (DBS). There is a lack of previous detailed data assessing the relationship 
between VNS and ANT- DBS. The aim of this study was to investigate the potential 
correlation between therapeutic responses to VNS and ANT- DBS.
Materials and Methods: A total of 11 patients with previous VNS therapy underwent 
ANT- DBS implantation. Monthly seizure counts starting from baseline before VNS 
extending to long- term DBS treatment were analyzed. The reasons for VNS discon-
tinuation were assessed.
Results: Altogether in 10 of 11 patients, the response to VNS seemed to be similar to 
the response to DBS therapy. Progressive response to VNS was likely to correlate 
with a progressive response to DBS in three of three patients. Partial response to 
VNS was associated with a fluctuating response pattern to DBS in two patients. Five 
of six nonresponders to VNS were also nonresponders to DBS. One of the VNS non-
responders obtained progressive response to DBS.
Conclusions: This is the first study to evaluate in detail the effect of both VNS and 
ANT- DBS in refractory epilepsy patients. There is a putative association between 
VNS and DBS responses suggesting the need for further studies.
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the effects of vagus nerve stimulation are still not fully understood 
(Roosevelt, Smith, Clough, Jensen, & Browning, 2006). VNS has been 
reported to reduce seizure frequencies by more than 50% in a group 
of patients with refractory epilepsy ranging from 30% (Ryvlin et al., 
2014) to 50% (Cukiert, 2015).
Deep brain stimulation is a promising treatment choice for re-
fractory focal epilepsy showing sustaining efficacy and safety 
(Salanova et al., 2015). DBS delivers currents directly to the ANT 
via electrodes implanted using stereotactic neurosurgical technique. 
The most optimal stimulation site is not unambiguously defined 
at this moment, and detailed anatomical variation of electrode lo-
cation may have an effect on the outcome (Lehtimäki et al., 2016; 
Möttönen et al., 2015).
There is some evidence suggesting common pathways between 
VNS and ANT- DBS therapy. In VNS, there are synaptic connections 
from the nucleus tractus solitarius to higher centers in the brain 
including thalamus (Rutecki, 1990). Furthermore, positron emis-
sion tomography (PET) and functional magnetic resonance imaging 
(fMRI) of the effects of VNS in human beings have confirmed the 
influence of the vagus nerve on higher brain structures (Ko et al., 
1996). These data suggest that the thalamus is consistently involved 
in VNS therapy.
The scientific basis for rational selection between different neu-
romodulation therapies is lacking. First, in the SANTE trial there 
was a subset of patients with previous VNS and/or resective sur-
gery, but no predictive association with DBS was reported (Fisher 
et al., 2010). Second, there are no follow- up studies evaluating the 
modification from VNS to DBS (or vice versa). Third, the comparison 
between the efficacies of these treatment modalities has been chal-
lenging as there are only case reports about patients with both VNS 
and DBS implanted (Franzini et al., 2009).
To our knowledge, this is the first study comparing in detail the 
long- term results of VNS and DBS therapy. Eleven patients with 
previous VNS therapy later underwent ANT- DBS. Monthly seizure 
counts from the baseline before VNS to long- term DBS treatment 
were analyzed.
2  | MATERIAL S AND METHODS
A total of 11 patients with previous VNS were implanted with ANT- 
DBS in Tampere University Hospital, Tampere, Finland, for refrac-
tory epilepsy. The VNS surgeries were performed in 2005- 2011 and 
DBS in 2010- 2013. All patients had been evaluated using inpatient 
video- EEG (electroencephalography) telemetry, 18- F- FDG- PET 
(fluorodeoxyglucose–positron emission tomography), and 3T MRI 
(3 Tesla magnetic resonance imaging) to identify potential epilepto-
genic zone/epileptic syndrome and evaluated for resective surgery. 
Clinical features of the patients are summarized in Table 1. The Study 
Plan was approved by the Ethical Committee of Tampere University 
Hospital, Tampere, Finland.
VNS was implanted microsurgically by exposing carotid sheath 
and the left vagus nerve, located medial to the jugular vein. A coil 
electrode (Cyberonics, USA) was wrapped around the vagus nerve, 
and the lead was fixed utilizing silicon anchors as recommended 
by the manufacturer. An internal pulse generator (Cyberonics) 
was implanted to the subcutaneous upper chest. From 10 of 11 
patients, the VNS device was surgically removed before the im-
plantation of DBS. DBS leads (3389, Medtronic) were stereotac-
tically implanted bilaterally under general anesthesia using visual 
targeting based on 3T MRI STIR (Short Tau Inversion Recovery) 
images (Lehtimäki et al., 2016; Möttönen et al., 2015). An internal 
pulse generator (Activa PC, Medtronic, USA) was implanted to the 
subcutaneous upper chest. DBS was started within few days after 
surgery.
The period of effective VNS therapy was defined as a successful 
delivery of significant therapeutic currents. The effective VNS ther-
apy could be terminated by turning the current OFF, depletion of 
the battery, or with a high impedance situation. The reasons for VNS 
discontinuation were re- evaluated. The varying VNS stimulation 
parameters were programmed individually to reach the best clinical 
outcome, the mean VNS settings at the end of the follow- up being 
the following: output current 2.1 mA, cycle 28.5 s ON / 66.5 s OFF, 
frequency 30 Hz, and pulse width 500 μs. The mean DBS settings 
at the end of the follow- up were the following: voltage 5.8 V (left), 
5.3 V (right), frequency 147.3 Hz, pulse width 124.5 μs, and cycle 
1 min ON / 5 min OFF. The programming of the DBS electrodes was 
planned according to MRI imaging.
The number of seizures during the year prior to VNS operation 
and afterward was evaluated from the patient records retrospec-
tively for the majority of patients. For five patients, the original 
seizure diaries were possible to obtain for seizure counting for the 
entire time period. The response to the stimulation is considered as 
“yes” if there is a decrease of more than 50% in the total number 
of seizures (6 months average seizure count in any time point with 
effective stimulation) compared to the baseline (12 months average 
seizure count before VNS/DBS implantation). A progressive VNS re-
sponder is defined as a patient with continuous progressive decline 
in seizure frequency during effective VNS therapy. A partial VNS 
responder is defined as a patient with an initial >50% decrease in 
seizure frequency but with fluctuating seizure count over long term. 
A progressive DBS responder is defined as a patient with contin-
uous progressive declination in seizure frequency during effective 
DBS therapy. A partial DBS responder is defined as initial >50% de-
crease in seizure frequency but with fluctuating seizure count over 
long term. A nonresponder to VNS or DBS is defined as less than 
50% decrease in seizure frequency over the course of neurostim-
ulation therapy. The patients having “partial response” cannot be 
considered as true responders as the effect does not sustain. We 
also briefly assessed the changes in drug treatment in every patient.
3  | RESULTS
Altogether in 10 patients of 11 (91%), VNS response was similar to 
the response pattern to DBS therapy. Three of 11 patients were 
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stable responders to VNS therapy. All these patients showed also 
progressive response to DBS therapy. Two patients had an initial 
response to VNS therapy that was not sustained over the course 
of years. All these patients demonstrated a partial response to DBS 
therapy. Six patients did not have satisfying effects by VNS based 
on the total number of seizures, and five of these patients did not 
have a response neither to DBS therapy. Only in one nonresponder 
to VNS therapy, there was a progressive response to DBS therapy. 
The details of seizure counts are shown in Figure 1 and patient char-
acteristics in Table 1.
At the time of the VNS initiation, three of the patients were 
on AED monotherapy, one patient on two AEDs, five patients on 
three AEDs, and two patients on four AEDs, 2.54 AEDs on average. 
Subsequently, while proceeding to DBS therapy, three patients were 
on AED monotherapy, none of them on two AEDs, six patients on 
three AEDs, one patient on four AEDs, and one patient on five AEDs. 
At the end of follow- up, they were on 2.91 AEDs on average; one 
patient was on AED monotherapy, two patients on two AEDs, five 
patients on three AEDs, and three patients on four AEDs. During the 
VNS therapy, seven new AED introductions were enacted, along with 
F IGURE  1 Mean monthly seizure count in six- month intervals. Legend: red arrow: VNS ON, red star: VNS OFF, red diamond: VNS high 
impedance in patients 3, 4, and 9, and battery depletion in patients 1 and 10, black arrow: DBS ON. Note: patient #6, second red arrow 
represents VNS battery change
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the five increases in dosage, six decreases in dosage, and five discon-
tinuations. During DBS therapy, seven new AED introductions, five 
increases, three decreases, and six discontinuations were executed. 
In one of the patients, no AED changes were made. The alterations in 
AED regimen enacted during the follow- up are presented in Table 2. 
In the group of nonresponders to both therapies, one AED intro-
duction was made between the neuromodulation therapies, causing 
the contradiction in total number of AEDs in the table. None of the 
responses to VNS or DBS are explained by the AED changes. The 
stimulation parameters were adjusted in every patient according to 
a similar protocol, with similar goal settings. We re- evaluated the 
stimulation setting histories and did not find any differences in the 
settings between the responders and nonresponders.
4  | DISCUSSION
According to our descriptive study, the response to ANT- DBS ther-
apy seems to be clinically associated with the response to previous 
trial of VNS therapy; if a patient had a partial or progressive positive 
effect of VNS, the ANT- DBS effect also showed same feature. If the 
patient was not responding to VNS therapy at all, the chances for a 
stable DBS response were reduced. Interestingly, this study provides 
for a first time a long- term follow- up data for more than 10 years of 
patients with both VNS and DBS therapies. The follow- up data of 
the SANTE trial have been published recently (Salanova et al., 2015): 
The median seizure reduction with ANT- DBS compared with base-
line for patients previously tried with VNS was 69% in five years, 
whereas the seizure reduction without prior VNS was also 69%. The 
reasons for VNS discontinuation were not reported. Therefore, their 
results differ from ours, as they did not report any similarities be-
tween the responses to VNS and ANT- DBS therapies.
This discrepancy between our results is most likely due to the 
different nature of the SANTE trial patient population and our study 
population. The patients in the SANTE trial with previous VNS ther-
apy were classified as nonresponders; however, the reasons for 
VNS explantation may vary including scar formation with imped-
ance problems, battery depletion, or dissatisfaction with obtained 
response, and the study might contain a group of patients with het-
erogeneous responses ranging from total nonresponders to partial 
responders. The patients for clinical trials are selected by more rig-
orous assessments than it is the case in everyday clinical practice. 
Most likely, in the SANTE trial, patients with a good response to 
VNS were not included. In our study population, some good VNS 
responders were indeed changed to DBS therapy, owing to the fact 
that at the time of the decision to proceed to DBS, the full effect 
of VNS was not acknowledged. Also, it has to be taken into con-
sideration that our patients were not fully satisfied with the VNS 
response and wanted to have it better in spite of being responder to 
VNS according to conventional evaluation.
Our study demonstrates that the reasons for discontinuing VNS 
treatment can be variable. Some patients did not have any effect of 
VNS on seizure frequency, therefore forming one distinct group. Most T
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of the patients with VNS treatment showed some response to the 
treatment. Furthermore, one patient group had an initial response ful-
filling the traditional criteria for responder, but later lost this response 
despite continuous effective VNS treatment forming a group of fluc-
tuating partial responders. This group cannot be considered as real 
responders, however, but form an interesting group of patients as they 
seem to respond to both VNS and ANT- DBS in a similar way, although 
the effect could also be explained by the fluctuating nature of the dis-
ease. A third group demonstrated a progressive decrease in seizure 
frequency until VNS therapy was either intentionally or unintention-
ally (battery depletion) terminated, or the therapy was no longer ef-
fective due to high impedance situation. There was a high impedance 
situation in three of 11 patients in our study group, which is quite ex-
ceptional and does not present the usual prevalence within our center. 
In high impedance situations, we tend to consider other treatment op-
tions along with the lead revision surgery. Another option for some of 
our patients could have been re- implantation of the VNS electrodes or 
simply battery replacement, instead of commencing the DBS therapy. 
In clinical setting, some VNS responders were considered as nonre-
sponders, which was realized afterward in the retrospective analysis. 
There is also an option of re- introducing VNS therapy in combination 
with ANT- DBS therapy for a possibility of additive efficacy. These 
findings highlight the importance of precise and detailed information 
about seizures, for example, seizure diaries and careful patient fol-
low- up, performed in our study in a single epilepsy center and by one 
epileptologist (JP). Furthermore, before altering the treatment method 
from VNS to DBS (or vice versa), a long- term follow- up of different 
seizure types and their frequency should be carefully assessed.
Along with the neurostimulation treatment, the patients were 
treated with antiepileptic drugs in accordance with standard clinical 
practice. Within the patients responding to VNS and DBS therapies, 
the AED regimen alterations do not seem to cause significant effects 
on seizure frequencies, even though the total AED amount being 
slightly increased during the follow- up period. None of the respond-
ers to VNS or DBS were so because of the AED changes.
There are data suggesting commonalities in VNS and ANT- DBS 
treatments. VNS increased cerebral blood flow (CBF) to the right 
thalamus among other structures such as the right posterior tem-
poral cortex (Ko et al., 1996). Additionally, in PET studies blood 
flow was increased to the inferior cerebellum, hypothalamus, 
and thalamus and decreased in the areas of the hippocampus, 
amygdala, and posterior cingulate gyrus during VNS (Henry et al., 
1998). In a subsequent study, increased right and left thalamic 
CBF correlated with decreased seizures suggesting that increased 
thalamic synaptic activities probably mediate some anticonvulsant 
effects of VNS (Henry et al., 1999). The main conclusions from 
these studies are that the thalamus is consistently involved in 
VNS therapy (Ben- Menachem, 2002), which lend support to the 
hypothesis that DBS stimulation of the ANT with prominent con-
nections with limbic circuitry affects similar structures with VNS. 
One might speculate that the similar responses to VNS and DBS 
therapy in our patient population might be partly explained by this 
neurobiological concept.
On the one hand, the main limitation of our study is the small 
number of patients with both VNS and DBS treatments limiting the 
possibilities for statistical analysis. On the other hand, all previous 
ANT- DBS studies with the exception of the SANTE (Salanova et al., 
2015) trial comprise similar numbers of patients. We also provide 
long- term follow- up data for more than seven years for each patient. 
Another significant weakness of our study is that the data are col-
lected retrospectively and the trial is unblinded and nonrandomized, 
therefore increasing the risk of bias in the results. Moreover, some 
segment of the response might be fallacious due to the fluctuating 
nature of the disease.
As a conclusion, this is the first study to evaluate in detail the 
effect of both VNS and ANT- DBS therapies in refractory epilepsy 
patients. Our study provides some provisional data suggesting an 
interesting relationship between responses to two modalities of 
neurostimulation. The main feature of our study is to form a hy-
pothesis for further analysis. Much information on the detailed VNS 
response in patients with subsequent ANT- DBS therapy is needed 
to assess the definitive significance of this putative association.
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